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Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory disorders, which require long term treatment to achieve
remission and to prevent relapses and cancer.While current therapies are effective in most cases, they can have rare but serious side
effects and are often associatedwith high costs. On the other hand, early discontinuation of an effective treatmentmay lead to a quick
relapse and to complications at the restart of therapy. Therefore it is essential to determine the optimal duration of maintenance
therapy, but clear guidelines are missing.Themost important questions when deciding whether to continue or withdraw therapy in
quiescentUC andCDpatients are the efficacy of the continuous treatment tomaintain remission in the long term, the frequency and
severity of side effects, and the chance of relapse after discontinuation of therapy. This review summarizes the current knowledge
on these topics with respect to 5-aminosalicylates, thiopurines, methotrexate, and biological therapies and collects information
regarding when and in which specific patient groups, in the absence of risk factors, can withdrawal of therapy be considered
without a high risk of relapse. Additionally, the particular aspect of colorectal cancer prevention by current therapies will also be
discussed.
1. Introduction
Inflammatory bowel diseases (IBD), such as ulcerative col-
itis (UC) and Crohn’s disease (CD), are chronic, immune-
mediated disorders of the gastrointestinal tract. In Western
countries the annual incidence rates can be as high as
6.3/100.000 for CD and 9.8/100.000 for UC, and the incidence
in developing countries is also increasing [1]. The disease
mostly affects individuals in their active, young and middle
ages, with significant economical consequences. Currently,
no curative treatment exists, but available therapies are able
to suppress the abnormal immune activation, achieve remis-
sion, and prevent relapses in many patients, enabling them to
lead a normal lifestyle. The efficacy of current treatments has
been proven by several studies and the daily clinical practice.
However, none of these medications are free from possible
side effects, and many of them are associated with high costs.
Therefore a new area of debate has emerged parallel to the
widespread use of these medications, namely, the question
of the optimal duration of treatment in IBD. According to
some views, maintenance therapy should be lifelong, as in
many other chronic diseases.Nevertheless, the clinical benefit
of maintenance therapy in symptom-free periods is not well
established, and the fear of possible side effects may incite
both patients and physicians to stop therapy once remission
is achieved. The most important questions in this debate are
the following: is the medication able to maintain remission
when taken on a regular basis or does the effect wane after
a certain period of time; how often and how serious are
side effects; what happens if the medication is withdrawn;
and which specific risk factors are associated with relapse?
This review aims to answer these questions by focusing on
available information and current opinions regarding the
optimal duration of therapy in UC and CD and, with the help
of risk factors, aims to collect data to determine a subgroup
of patients who have a very low relapse rate and where the
discontinuation of therapy may be possible.
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2. 5-Aminosalicylic Compounds
2.1. Efficacy of Maintenance Therapy in the Long Term. 5-
Aminosalicylates (5-ASA) represent the first line therapy in
mild and moderate UC patients. Modern 5-ASA preparates
are all related to sulphasalazine, a drug reported as early
as 1942 to have therapeutic effects in UC patients [2].
Subsequently, several other formulations of 5-ASA without
the sulpha moiety have been developed to minimize possible
side effects and provide therapeutic effects. Different prepa-
rations of 5-ASA, such as controlled release [3], pH-sensitive,
polymer-coated [4] mesalamine formulations, or olsalazine
containing two 5-ASA molecules without the sulpha moiety
[5], have all been shown to maintain remission significantly
better than placebo in 6–12-month, double-blind, placebo-
controlled studies in quiescent UC patients. Most studies
investigating the efficacy of 5-ASA as a maintenance therapy
were only 6 or 12 months in duration—too short to test
whether the effect wanes by time. Nevertheless, one study
following 150 UC patients treated with fixed doses of oral
mesalamine until the appearance of the first relapse found
that, aside from 19 dropouts, all 150 patients had relapsed
within 9 years [6]. The peak period of relapse appeared
between 2 and 3 years, and none of the followed patients
developed cancer.
The efficacy of 5-ASA to induce or maintain remission
in CD has conflicting results. Indeed, a systematic review
has found no evidence showing that 5-ASA preparations are
superior to placebo for themaintenance ofmedically induced
remission in patients with CD [7]. According to the latest
guideline of the European Crohn’s and Colitis Organization
(ECCO), 5-ASA preparations are not recommended for
maintenance of medically induced remission in CD [8].
2.2.Withdrawal. Specific data on the withdrawal of 5-ASA in
UCpatients in remission is scarce. In 1973 two similar double-
blind withdrawal studies were performed with an opposite
outcome [9, 10]. Study details can be seen in Table 1. As there
was no significant difference between the relapse rates of
patients whowere switched to placebo andwho continued on
sulphasalazine, the conclusion of the first study was that it is
safe to stop sulphasalazine maintenance therapy in patients
who are symptom-free for at least 12 months [9]. To the
contrary, as the relapse rates were four times higher in the
placebo group, the authors of the second study concluded
that salazopyrine maintenance therapy should be continued
in UC patients on remission unless there are harmful side
effects [10]. The differences between the results may lie in
the fact that, in the former study, inclusion and the definition
of relapse were based exclusively on symptoms, while in the
latter, sigmoidoscopy and rectal biopsy were also performed
in a blind manner. Furthermore, the low relapse rate in the
treatment group in the second study may be attributed to the
high compliance of patients, confirmed by a blood test at 3
months [10].
As the usefulness of maintenance therapy in ulcerative
colitis was still unclear, Ardizzone and colleagues performed
a randomized, double-blind withdrawal study with 5-ASA
(Asacol, 1.2 g/d) to clarify this point in 1999 (Table 1) [11].
Patients were allocated to two groups according to the length
of previous remission. Contrary to Group A (remission: 1-
2 years), in the group in remission for over 24 months
(Group B), the withdrawal of 5-ASA did not influence the
relapse rates.Nevertheless, the authors admit that their results
must be treated with caution: the sample size was small
and patients in Group B were significantly older with longer
disease duration than those in Group A.This may explain the
results in Group B, as older UC patients and patients with
longer disease duration tend to relapse less frequently [33];
therefore the lack of benefit of 5-ASA in this group compared
to placebo may reflect the natural history of the disease. The
cautious conclusion of this study was that 5-ASA prophylaxis
is necessary in patients who are in remission for less than 2
years but questioned whether patients in prolonged clinical,
endoscopic, and histological remission with a very low risk
of relapse should be treated indefinitely. Nearly ten years later
two of the authors have stated that although their results may
suggest that a special subgroup of patients could discontinue
5-ASA treatment, the potential effect of 5-ASA to reduce
cancer risk still makes long term treatment necessary [34].
2.3. Intermittent Therapy. Whether continuous therapy can
be replaced by intermittent treatment is also debatable. Fifty
UC patients in remission for at least 1 month were enrolled
in a 12-month clinical trial performed in Italy [35]. Half of
the patients received 5-ASA daily p.o., while the rest of them
received 5-ASA treatments only in the first week of each
month. Interestingly, the relapse rates were similar in the
two groups at the end of the 12-month period. This outcome
agreed with previous preliminary results fromDickinson and
colleagues, who followed 28 UC patients in remission for 12
months and found that “on-demand” sulphasalazine therapy
was equally effective as continuous treatment to prevent
relapse [36]. Some authors claim that the lack of benefit
from continuous 5-ASA treatment compared to intermittent
treatment may come from the low adherence of UC patients
to long term treatment [37]. Indeed, these authors speculate
that even patients who should be taking 5-ASA on a regular
basis tend to use it “on-demand”; that is, they forget their
medication until their symptoms remind them to take it
again. Therefore the best way to decrease relapse rate would
be to find the key to patient adherence to drugs, such as
through better patient education.
2.4. Possible Side Effects. Early papers have already described
side effects of sulphasalazine, the most frequent being
gastrointestinal symptoms such as nausea, vomiting, or
epigastric discomfort, which affect up to 45% percent of
patients [2, 3]. Contrary to these symptoms which are
signs of a dose-related intolerance, non-dose-related idiosyn-
cratic reactions also exist [38]. These include hypersensi-
tivity rashes, diarrhea, haematological complications, such
as haemolytic anemia or agranulocytosis, and pulmonary
and hepatic dysfunction [38–40]. However, 80% of patients
intolerant to sulphasalazine are able to tolerate modern 5-
ASA preparates [38]. Common side effects of the latter are
similar to that of sulphasalazine, such as nausea, vomiting,
abdominal pain, headache, and rash [41], but the frequency
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Table 2: Adverse events in pro- and retrospective studies.
Author Year Drug Adverse events/side effects (number ofcases)
Death from (number of
cases)
Dissanayake and
Truelove [10] 1973 Sulphasalazine Nausea (2); headache (1) 0
Ardizzone
et al. [11] 1999 5-ASA Abdominal pain, bloating, diarrhea (3) 0
O’Donoghue
et al. [13] 1978 Azathioprine Pancytopenia (1)
Hawthorne
et al. [12] 1992 Azathioprine Transient bone marrow suppression (2) 0
Bouhnik
et al. [16] 1996 Azathioprine/6-mercaptopurine
Leucopenia (18), thrombocytopenia (2),
liver abnormalities (4), urinary tract
infections (4), malignant melanoma (1),
cutaneous basal cell carcinoma (1), renal
carcinoma (1), and brain lymphoma (1)
0
Le´mann
et al. [15] 2005 Azathioprine
Mild leucopenia reversed with dose
reduction (1)
Myelodysplastic
syndrome (1)
Mantzaris
et al. [17] 2007 Azathioprine
Headache (17), paraesthesias (1), flu (7),
herpes simplex (5), herpes zoster (2),
bronchitis (2), transient psoriasis rash (1),
transient leucopenia (3), significant
leucopenia (2), no malignancies
0
Treton et al. [18] 2009 Azathioprine Moderate leucopenia, reversed by doseadjustment (3)
Breast cancer (1);
disseminated varicella (1
treated with azathioprine
in combination with
infliximab)
Fraser et al. [19] 2002 Methotrexate
Nausea and vomiting (7), increased diarrhea
(2), severe stomatitis (1), leucopenia (3),
pneumonia (1), fever (1), shingles (1),
elevated liver enzyme (2), photosensitive
rash (1)
Multiple organ failure (1)
Dome`nech
et al. [20] 2005 Infliximab
Acute infusion reactions (5); no
malignancies, opportunistic infections 0
Schnitzler
et al. [21] 2009 Infliximab
Acute infusion reactions (15), delayed
infusion reactions (33), herpes zoster (1),
abdominal tuberculosis (1), neuritis optica
(1), central demyalinising lesion (1),
extensive multiple sclerosis-like neurological
symptoms (1)
Aspergillus infection (1)
Louis et al. [22] 2012 Infliximab No serious adverse events 0
Molna´r
et al. [23] 2013 Infliximab or adalimumab In 10.9% of patients, none of them serious 0
Farkas et al. [24] 2013 Infliximab No serious adverse events 0
of these adverse events is comparable to that of placebo [42].
Severe but very rare adverse events may manifest in acute
pancreatitis, interstitial nephritis, liver, or pulmonary injury
[43]. A recent phase 3, multicenter, 24-month, open-label
study focused on side effects in patients in remission from
mild to moderate UC, taking mesalamine granules 1.5 g once
daily [44]. The authors reported nasopharyngitis to be the
most frequent adverse event (13.9%), followed by headache
(11.6%) and diarrhea (10.8%). Pancreatic, renal, and hepatic
adverse events occurred in less than 6% of patients. Side
effects in the above mentioned studies can be seen in Table 2.
3. Thiopurines
3.1. Efficacy of Maintenance Therapy in the Long Term. 6-
Mercaptopurine and azathioprine are antimetabolite pro-
drugs, belonging to the group of thiopurines. It has been
discovered early that these drugs work with a time lag of
several months in IBD patients [45], and their use to induce
remission in CD and UC are controversial [8, 46]. However,
the capacity of these drugs to maintain remission in the long
term has been proven by single studies and meta-analyses
in both CD [47, 48] and UC [49, 50]. Furthermore, due to
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their steroid sparing effect, they are beneficial for steroid-
dependent and steroid-refractory patients [48, 51]. Con-
cerning the efficacy in the long term, a retrospective study
conducted in Oxford over a 30-year time period evaluated
altogether 622 IBD patients treated with azathioprine [26].
The remission rates were 45% for CD and 58% for UC. At
12, 24, 36, 48, and 60 months the proportion of patients still
in remission was 0.95, 0.90, 0.69, 0.63, and 0.62, respectively,
and no difference was found between CD and UC patients in
relapse rates.The authors have concluded that azathioprine is
effective as a long-term maintenance therapy, and the effect
does not “wear off” for up to 5 years.
3.2. Withdrawal. Compared to aminosalicylates, more
attempts have been made to clarify if thiopurines can be
withdrawn in UC and CD patients in remission, mostly
because the fear from their possible serious side effects
makes physicians reluctant to prescribe these medications in
the long term.
3.2.1. UC. The only placebo-controlled, double-blind with-
drawal trial on UC patients was conducted in 1992 (Table 1)
[12]. Patients were taking azathioprine for 6 months or more
and were allocated to two groups according to their disease
status, namely, in full remission for twomonths ormorewith-
out corticosteroids or having a chronic stable disease. The
latter was defined as having low-grade symptoms or symptom
control with low doses of corticosteroids. The results clearly
showed that azathioprine was effective in the maintenance of
remission in quiescent UC patients, as withdrawal resulted
in twice as many relapses. Patients in a longer remission (at
least 6 months, with a median of 12 months) also benefit
from continuing maintenance therapy. Data also has shown
that, for those patients, who did not achieve remission with
azathioprine treatment within 6 months, there is probably no
benefit in taking it.
The further available studies assessing the effect of thiop-
urine withdrawal in UC were retrospective, evaluating the
outcome in patients, who stopped thiopurine treatment while
in remission (Table 3). A study reviewing charts of patients
treated between 1973 and 1992 with 6-mercaptopurine has
shown a very high relapse rate after the withdrawal of the
drug, and the authors have suggested a long term treatment
in those UC patients who respond to therapy [25].
The previously mentioned study from Oxford evaluated
not only the long term efficacy but also the relapse rates
in 222 IBD (143UC and 79CD) patients after stopping aza-
thioprine treatment while being in remission (Table 2) [26].
No statistical difference was observed between UC and CD
patients concerning relapse rates, but relapse rates weremuch
higher in patients who stopped azathioprine compared to
those who continued it. The authors have concluded that
azathioprine is effective with a low toxicity in IBD patients
for up to 5 years. However, they cautiously refrained from
therapeutic suggestions.
In a study conducted in Italy, relapse rates after azathio-
prine withdrawal in steroid-free remission were high, simi-
larly to previous studies (Table 2) [27]. In this study, several
predictive factors of relapse after azathioprine withdrawal
have been identified, which will be detailed later. In 10% of
cases, the outcome was colectomy, which could be predicted
by drug-related toxicity as the cause of azathioprine with-
drawal, no post-azathioprine drug therapy, and treatment
duration.
3.2.2. CD. In CD, the picture is more complex. An early
double-blind withdrawal trial showed the efficacy of azathio-
prinemaintenance therapy compared to placebo, irrespective
of complementer anti-inflammatory drug use (Table 1) [13].
One patient developed pancytopenia and died despite of the
withdrawal of azathioprine. This patient had been taking
azathioprine for more than ten years before entering the
trial, where he continued with the azathioprine treatment.
These results suggested that azathioprine is efficient in the
maintenance of remission in the long term but shed light also
on the possible fatal side effects, and the optimal duration of
therapy was not yet determined.
The efficacy of thiopurines in the long term was also
confirmed by a follow-up study on 120CD patients (Table 3)
[28]. The median length of remission in patients who
continued on 6-mercaptopurine was 32 months, while it
was only 16 months in patients who stopped treatment.
The authors concluded that 6-mercaptopurine should be
continued indefinitely, if the drug is well tolerated.
A retrospective study in France on CD patients showed
no further benefit during and after the fifth year of remis-
sion in patients who continued to take azathioprine or 6-
mercaptopurine compared to those who had stopped it
(Table 3) [16]. This study was the first to raise the suggestion
that thiopurines may be discontinued in CD patients who are
in remission for at least 4 years.
A small randomized open withdrawal trial on CD
patients in stable remission without steroids have confirmed
the efficacy and need to continue azathioprine at least for
3 years, but did not give information on the previously
questioned efficacy beyond 4 years (Table 1) [14].
A multicenter European retrospective study on UC and
CD patients has shown that, in the first 4 years, thiopurines
were equally efficient in the two diseases (Table 3) [29]. Long
term therapy beyond 4 years had a significant beneficial
effect on disease activity in CD patients and reduced steroid
requirement in both CD and UC. Nevertheless, in CD
patients in steroid-free remission, no relapse was seen after
the discontinuation of the drug after 3-4 years. Therefore
it has been concluded that discontinuation of thiopurine
therapy may be considered in this specific group of patients.
However, in other CD and UC patients the continuation of
treatment is recommended.
So far, the opinion that thiopurine therapy may lose its
benefit after 4 years of treatment in CD patients was based
only on retrospective results [16, 29] and later has been chal-
lenged by several authors. Indeed, inspired by their previous
results, the same French group conducted a randomized,
double-blind, controlled noninferiority withdrawal trial to
confirm their observation that CD patients in remission
on azathioprine for more than 3.5 years are at low risk
of relapse when azathioprine is discontinued (Table 1) [15].
Although included patients were steroid-free for at least 42
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months, azathioprine continuation was found superior to
azathioprine withdrawal, and the authors concluded that the
prolonged treatment with azathioprine should be continued
beyond 3.5 years.
The extension of this study was published four years later
[18]. All patients in remission, who had stopped azathioprine
following randomization in placebo arm in the previous trial
(43 patients) and those who had discontinued azathioprine
after the end of that trial (23 patients) were included. The
median followup was 54.5 months. Out of the 66 patients, 32
(48.4%) relapsed during follow up. The cumulative probabil-
ities of relapse at 1 year and 3 and 5 years were 14%, 52.8%,
and 62.7%, respectively. Time to relapse curves of those
patients, who had stopped azathioprine due to randomization
in placebo group (median treatment duration: 62 months)
were not different from thosewho stopped treatment after the
end of the trial (median treatment duration: 80 months).
A further study aimed to assess, whether the effect of
azathioprine wears off after 4 years in CD patients [17].
Namely, one hundred steroid-dependent CD patients were
allocated to two groups, depending on the previous duration
of remission with azathioprine treatment and followed for
one year. Steroids and 5-ASA were tapered off before enroll-
ment. Relapse rate was 19.6% in the group of 58 patients
in remission for 2–4 years and 11.9% in the group of 42
patients in remission for more than 4 years. This study has
demonstrated that the effect of azathioprine does not wane
after 4 years of therapy.
It is interesting to note that none of the above-mentioned
studies have evaluated 6-thioguanine levels at the time of
therapy withdrawal and the risk of relapse. 6-thioguanine
nucleotides are the active metabolites of azathioprine, and
their higher level in red blood cells in CD and UC patients
is associated with an increased rate of steroid-free remission
[52].
3.3. Possible Side Effects. 5 to 10% of patients do not tol-
erate thiopurines due to idiosyncratic adverse events, most
commonly fever, nausea, diarrhea, rash, abdominal pain,
pancreatitis, and allergic reactions that mostly occur within
the first 2-3 weeks of therapy [53, 54]. Myelosuppression
and consequent leucopenia and/or thrombocytopenia are the
most common and potentially lethal hematological compli-
cations, which develop in 2.2 to 15% of patients [53, 55]. The
onset of myelosuppression can range from 2 weeks to 11 years
from the initiation of therapy and is usually reversed by dose
reduction, but severe opportunistic infections may poten-
tially occur [55, 56]. A mild elevation in liver function tests is
not uncommon and usually responds to dose reduction [53].
Less frequently severe hepatotoxicity, for example, nodular
regenerative hyperplasia, may develop, leading to progressive
liver damage and portal hypertension.Themost delicate topic
regarding long term consequences of thiopurine therapy is
the incidence of cancer and lymphomas. Indeed, patients
under thiopurine therapy are exposed to an increased risk
of nonmelanoma skin cancer; therefore they should use
protection against UV radiation and undergo lifelong regular
dermatologic checkups [53, 57, 58]. Regarding lymphomas, a
meta-analysis has found a fourfold risk in IBD patients on
thiopurine treatment [59], while a large prospective study
has identified a 5.28 hazard ratio in IBD patients taking
thiopurines [60]. Whether the increased risk is related to the
drug or to the disease itself is not known, but discontinuation
of therapy can decrease the risk of lymphomas [61]. Young,
smoking females, but not nonsmokers, are at increased risk of
cervical dysplasia [62]. Still, other authors have observed no
increased risk of malignancy in IBD patients on thiopurine
treatment [63, 64]. Side effects in the above-mentioned
studies are shown in Table 2.
4. Methotrexate
4.1. Efficacy of Maintenance Therapy. Methotrexate is gener-
ally reserved for CD patients with active or relapsing disease,
who are refractory to or intolerant of thiopurines or anti-
TNF agents [8]. A recent meta-analysis has concluded that
methotrexate at a dose of 15mg/week by intramuscular route
is superior to placebo for maintenance of remission in CD
for up to 40 weeks, while data on oral route are insufficient
for a clear conclusion [65]. In the case of CD patients
on methotrexate maintenance therapy, the probability of
remaining in remission ranged from 71 to 90% at one year,
59 to 73% at two years, and 51 to 52% at three years [19, 66].
Although some studies have demonstrated beneficial
effects of methotrexate in the maintenance of remission in
UC, contradictory results also exist [19]. Different doses
and the route of administration highly affect the outcome;
intramuscular route has been found the most effective. A
study from a Spanish group found that 90%, 80%, and 50% of
UC patients on methotrexate therapy were still on remission
at 1 year and 2 and 3 years, respectively [67]. The ECCO
consensus stated that the evidence is currently insufficient to
recommend methotrexate for UC [8].
4.2. Withdrawal. There is very little data on discontinuation
of methotrexate therapy in IBD patients on remission, as spe-
cific withdrawal studies are missing. A previously mentioned
retrospective study reported an extremely high relapse rate
after discontinuation of therapy (Table 3) [19].
4.3. Possible Side Effects. Safety concerns of methotrexate
have a large impact on its limited use in IBD patients. Studies
report the incidence of side effects rising up to 22%, which
lead to a discontinuation of treatment in 10–18% of cases [67].
Short term side effects are mainly gastrointestinal, such as
nausea, vomiting, diarrhea, and stomatitis, which can mostly
be prevented by the coadministration of folic acid two or
three days apart from methotrexate [8]. In the long term,
bone marrow toxicity, hepatotoxicity, and pneumonitis can
occur. The occurrence of bone marrow toxicity is low in
patients with normal renal function and it can be further
reduced by coadministration of folic acid [68]. A meta-
analysis of clinical trials has found a low occurrence of
hepatotoxicity (defined as up to a 2-fold increase over the
upper limit of the normal hepatic aminotransferase levels)
in IBD patients treated with methotrexate, with a rate of
0.9 per 100 person-months [69]. In children, abnormal liver
biochemistry was detected in 10.2% of cases, dose reductions
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were required in 6.4%, while in 4.5% of cases methotrexate
had to be completely stopped, according to a large meta-
analysis [70]. Therefore risk factors of hepatotoxicity, for
example, alcohol abuse, chronic viral infections, diabetes, and
obesity, must be ruled out before the initiation of therapy, and
liver monitoring during the course of treatment is extremely
important [67]. The prevalence of pneumonitis is reported
to be 0.3–7.5% in rheumatoid arthritis patients [71], but
no cases were reported in large series [72]. Side effects in
the above-mentioned retrospective study from Fraser are
detailed in Table 2. According to new expert opinions, the
side effect profile of methotrexate is not worse than that
of azathioprine. Therefore a more widespread use in IBD,
similarly to rheumatologic diseases, can be expected in the
future.
5. Biological Therapies
5.1. Efficacy of Maintenance Therapy. Infliximab, a chimeric
monoclonal antibody against tumor necrosis factor alpha
(TNF-𝛼), and adalimumab, a fully human monoclonal IgG1
anti-TNF-𝛼 antibody, were both found effective as a mainte-
nance therapy in UC and CD [73–77]. Regarding the effects
in the long term, in a group of moderate-to-severe, therapy
refractory UC patients, 67% have achieved response with
infliximab therapy, and out of these patients, 68% had a
sustained response during a median followup of 33 months
[73]. In CDpatients treatedwith infliximab, sustained clinical
benefit was observed in 63.4% of patients up to a median
followup of 55 months, while 68.3% of patients were still
on infliximab therapy [21]. Furthermore, in a retrospective
study, in CD patients with complete response on infliximab
the cumulative probability of being free of relapse was 97.2%
at 12 months, 90.3% at 24 months, 81.7% at 36 months, 73.5%
at 48 months, and 61.3% at 51 months [78]. From this data it
can be concluded that infliximab is effective in CD patients
in the long term, but, as a systematic review has pointed
out, the annual risk for loss of infliximab response is around
13% per patient-year, which requires therapy intensification
[79]. Adalimumabhas been found significantlymore effective
compared to placebo for the maintenance of remission in UC
andCDpatients for up to one year [75–77]. A 4-year followup
of adalimumab treated UC patients has recently reported
that remission, mucosal healing, and improved quality of
life is well maintained by adalimumab up to the 4th year of
treatment [80].
5.2. Withdrawal
5.2.1. UC. In a Danish observational, retrospective study,
out of 97UC patients, 28 (30%) have stopped infliximab
therapy due to a stable steroid-free remission, according to
their treating physicians’ global judgment (Table 3) [30]. 25%
of patients relapsed within one year, and no factors could
be identified that correlated with relapse or with prolonged
remission (remission > 1 year). Concomitant immunosup-
pression did not influence the relapse rate.
According to the Hungarian National Health Insurance
Fund Administration reimbursement regulations, biological
therapy must be discontinued after a 1-year treatment period
in UC and CD patients who achieved remission. These
regulations have created the basis to observe the effects of
infliximab and adalimumab withdrawal in IBD patients [23,
24]. In a recent prospective observational study, UC patients,
who have achieved clinical remission after a 1-year period of
infliximab therapy, were followed after the discontinuation of
treatment (Table 3) [24]. 35% of patients relapsed within one
year after the withdrawal of infliximab therapy.
5.2.2. CD. A study conducted in Spain has collected clinical
data from three centers of the outcome after discontinuation
of infliximab therapy in CD patients (Table 3) [20]. The
cumulative probability of being relapse-freewas 45%and 34%
at 6 and 12 months in case of perianal disease, while in case
of luminal CD it was 83% at 12 months. Perianal disease was
the only factor predicting relapse. The authors suggest that
infliximab discontinuation is not recommended in perianal
CD, as early relapse is extremely common.
In a large observational study evaluating the long term
effects of infliximab therapy in CD, treatment was stopped
in 110 patients in remission (Table 3) [21]. The authors have
found that one in three patients can stop infliximab therapy
and still stay in remission while continuing on immuno-
suppressants, but no factor could be identified which would
predict a favourable outcome after drug withdrawal. In a
longitudinal cohort study conducted in Canada, data of CD
patients who had discontinued infliximab treatment while
in infliximab-induced steroid-free remission was evaluated
(Table 3) [32]. Similarly as in the previous study, 35% of
patients remained in sustained remission after infliximab
withdrawal, but the authors were unable to find a factor
responsible for this outcome. In the previously mentioned
Danish retrospective study, 53 of 219 CD patients (24%)
discontinued infliximab therapy due to clinical remission
(Table 3) [30]. Around 40% of these patients could benefit
from a sustained remission. Those CD patients who relapsed
had significantly longer disease duration, but no factor was
associated with a prolonged remission.
In a multicenter prospective study called STORI, 115 CD
patients were included, who were treated for at least 1 year
with infliximab and an antimetabolite (methotrexate/aza-
thioprine/6-mercaptopurine), and have been in cortico-
steroid-free remission for at least 6 months before inclusion
(Table 3) [22]. The relapse rate was nearly 44% after 1 year
of infliximab withdrawal. Several individual risk factors for
relapse were identified in this study, which will be detailed
later. The authors suggest that by assessing these parameters,
patients with low risk of relapse can be selected and in these
patients, infliximab can be stopped. Others have claimed
that the elevated CDEIS score, increased CRP and fecal
calprotectin levels show that, in the case of these patients,
the disease was not under “tight control,” and in the era of
mucosal healing, mucosal flair would better represent the
outcome than clinical relapse [81].
A multicenter, prospective observational study called
RASH followed 121 CD patients who were in clinical remis-
sion after 1 year therapy with infliximab (𝑛 = 87) or
adalimumab (𝑛 = 34) (Table 3) [23]. Similarly to the previous
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study, one-year relapse rate was 45%, and many risk factors
predicting a relapse after withdrawal have been identified. A
huge difference between the patient population of the RASH
study and the STORI study was that, in the former, biological
treatments were stopped even if steroids could not be tapered
off, while, in the latter, patients were in a corticosteroid-free
remission 6 months before inclusion.
5.3. Possible Side Effects. Although infliximab and adali-
mumab are considered safe in the short term, many concerns
exist regarding their long term use. A large case-control
study with a mean followup of 1.9 years has shown no
difference between the mortality rate of infliximab-treated
and noninfliximab treated CD patients [82]. Similarly, a
retrospective cohort study with a median follow-up time of
58months (of IBD patients) and 144months (of controls) has
found no difference between the mortality rate of infliximab-
treated IBD patients and of IBD patients not receiving any
biological therapy [83]. However, in this study the death of an
elderly patient due to Aspergillus sepsis was directly related
to infliximab therapy. Indeed, one of the main concerns
is the increased risk of infections. The retrospective study
did not find a significant difference between the infection
rates of the two groups, but the risk of infections was sig-
nificantly increased when concomitant corticosteroids were
administered [83]. Additionally, two patients on infliximab
were diagnosedwith extraintestinal tuberculosis, underlining
the importance of detecting mycobacterial infection before
the start of biological therapy, even though it is known
that response to a tuberculin skin test may be anergic in
up to 83% of CD patients on immunosuppressive therapy
[84]. In the case-control study, infliximab was not identified
as an independent predictor of serious infections, contrary
to corticosteroid use [82]. Another important concern is
the development of malignancies in patients on biological
therapies. In placebo-controlled trials, according to a system-
atic review, the risk of malignancies was not increased in
patients treated with anti-TNF-𝛼 therapy, but the followup
was only one year, and therefore no conclusions can be
drawn concerning the long term effects [85]. In the previously
mentioned retrospective study with a follow-up time of
more than 5 years, the risk of malignancies was also not
elevated in infliximab-treated IBD patients [83]. At this
point, an evidence-based guideline cannot be given, but tight
surveillance is advisable to detect precancerous lesions and
early cancers in patients receiving biological treatments [51].
A further rare but specific problem associated with the use of
anti-TNF-𝛼 treatment is demyelinating disease, which usually
mimics multiple sclerosis [51, 83]. In a retrospective analysis
aiming to determine the frequency of this adverse event,
during a four-year period of 550 rheumatoid arthritis patients
treated with anti-TNF-𝛼 agents, 6 cases of demyelinating
disease were identified [86]. Further, frequent complications
associated with the use of infliximab are dermatological
symptoms, often diagnosed as psoriasiform dermatitis and
eczema [83]. These symptoms can occur in up to 20% of
patients, but in most cases respond well to topical steroid
treatment and rarely require the discontinuation of therapy.
Side effects of the previously detailed withdrawal studies are
shown in Table 2.
6. Specific Aspects
6.1. Length of Previous Remission. It is an important question
whether a long remission while on therapy can predict
a sustained remission after drug withdrawal. Results are
controversial, and many of them point to the direction that
the duration of previous remission does not predict the
outcome after drug withdrawal (Table 4). Time to relapse
and/or the relapse rate after withdrawal were similar in
patient groups regardless of the length of previous therapy
with the drug or the duration of preceding remission inmany
studies [9, 10, 13, 18, 26, 28]. In the study showing a better
outcome after 5-ASA withdrawal in patients in remission for
more than 2 years compared to those in remission for 1-2
years, the patients with longer remission were significantly
older, which can explain the observed difference, as lower
age has been found a predictive factor of relapse in several
studies [11]. In the study with azathioprine withdrawal in UC
patients, a significant difference could be found only between
the groups of a short treatment duration (3–6 months) and
very long treatment duration > 48 months [27]. Altogether
the results suggest that, except from a very short treatment
time, other factors, for example, the depth of remission, are
more important than the duration of remission.
6.2. Mucosal Healing. Mucosal healing is defined as the
“complete absence of all inflammatory and ulcerative lesions
in all segments of gut” at endoscopy [87]. Several different
endoscopic scoring systems have been used in clinical trials
on UC patients to assess endoscopic activity, the Mayo
endoscopic score being the most popular. Recently mucosal
healing is often used as an important endpoint to assess the
therapeutic effect in UC and CD. It is associated with a lower
rate of hospitalisation and surgery, but its predictive role of a
sustained remission after drug withdrawal is not yet clear.
As mucosal healing is a novel entity, its connection with
a prolonged remission in earlier drug withdrawal studies
could not been tested. In the study of Dissanayake and
Truelove a sigmoidoscopy with rectal biopsy was performed
at enrollment in the study, in case of a suspected relapse and
at the end of the 6-month study period [10]. Only patients
with a normal sigmoidoscopic finding and a rectal biopsy
without significant inflammation entered the withdrawal
study. Similarly, in the study of Ardizzone, only patients
with no signs of active inflammation on sigmoidoscopy
and with a stable histological remission, defined as grade 0
(absence of neutrophils) according to the criteria of Truelove
and Richards, were selected for the study [11]. Due to this
design no information is available on the association between
endoscopic remission and the rate of relapse after 5-ASA
discontinuation.
Similarly, in case of thiopurines, no studies were designed
specifically to answer if there is a link between the
endoscopic-histological picture at therapy withdrawal and
the risk of relapse. In the study of Hawthorne et al. a
sigmoidoscopy was performed at the inclusion, and only
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Table 4: The influence of the duration of remission or previous therapy on the outcome after drug withdrawal.
Author Year Disease Drug
Length of previous
remission in the
different groups
Length of previous
therapy with the
drug in the different
groups
Better outcome at
withdrawal after
longer
remission/therapy
Riis et al. [9] 1973 UC Sulphasalazine 12–24 months versus
>24 months No
Dissanayake and Truelove [10] 1973 UC Sulphasalazine 1–3 years versus >3years No
Ardizzone et al. [11] 1999 UC 5-ASA 1-2 years versus >2years Yes
Hawthorne et al. [12] 1992 UC Azathioprine Continuous analysis Yes; 𝑝 = 0.1
Fraser et al. [26] 2002 UC Azathioprine <2 years versus 2–4years vs. >4 years No
Cassinotti et al. [27] 2009 UC Azathioprine 3–6 months versus48 months Yes
O’Donoghue et al. [13] 1978 CD Azathioprine <1 years versus 1-2years versus >2 years
<1 years versus 1-2
years versus >2 years No
Bouhnik et al. [16] 1996 CD Azathioprine 6 months–4 yearsversus >4 years Yes
Kim et al. [28] 1999 CD 6-Mercaptopurine
<1 year versus 1-2
years versus 2-3
years versus >3 years
No
Holtmann et al. [29] 2006 CD Azathioprine/6-mercaptopurine
<3 years versus 3-4
years versus >4 years No
Treton et al. [18] 2009 CD Azathioprine Median 62 monthsversus 80 months No
patients with a mucosal appearance of grade 0 or 1 (Baron,
0: normal mucosa; 1: granular or oedematous mucosa with
loss of vascular pattern) were eligible for the study [12].
However, no data is available concerning the difference of the
relapse rate between patients with grade 0 or grade 1 mucosal
appearance. In case of the study of Le´mann and colleagues,
out of the 83 enrolled patients, 45 had a colonoscopy at
baseline, and only 36%of themhad completemucosal healing
[15]. The authors state that endoscopic lesions or ulcerations
were not predictive of relapse, but data on the risk of relapse
in patients with or without mucosal healing are not shown.
Concerning biological therapy,more information is avail-
able on the topic. Indeed, in UC patients, no significant
correlation could be seen between mucosal healing at the
end of infliximab therapy and the outcome of withdrawal
[24]. Similarly, in the RASH study, no correlation was found
between mucosal healing and the need to restart biological
therapy in CD patients, although the number of patients with
endoscopic evaluation was limited [23]. Furthermore, in a
recent prospective study designed with the aim to answer this
question, mucosal healing could not predict the outcome of
anti-TNF-𝛼 therapy withdrawal in 41 CD and 22UC patients
(Table 3) [31]. In this study, all patients received either
infliximab or adalimumab treatment for 12 months before
withdrawal and were followed for one year. At the end of the
treatment period, mucosal healing was achieved in 56% of
CD and 32% of UC patients, while deep remission (mucosal
healing + clinical remission) in 54% of CD and 23% of UC
patients. Interestingly, 59% of CD and 100% of UC patients
in deep remission had to be retreated within one year, while
out of the total study population, 78% of CD and 59% of
UC patients.These results suggest that evaluation of mucosal
healing should not replace the assessment of clinical activity
and the patient’s general condition, when considering therapy
withdrawal.
The use of a new treatment target, the so-called histolog-
ical remission, is emerging in IBD [88], which may appear
as a novel endpoint in withdrawal studies in the future.
However, at present numerous histological scoring systems
exist in IBD, without being properly validated. The role of
histological remission to predict complications in IBD is not
well established, and it is not yet clear if this new term can be
used as an endpoint in the treatment of IBD.
6.3. Chemoprevention. The increased risk of colorectal cancer
(CRC) in UC has long been recognized. An early study
performed on UC patients, who grew up in the era when
effective treatment for IBD hardly existed, found a 20%
risk of colon cancer per decade in children at risk, start-
ing after 10 years of disease onset [89]. It has since been
observed that the risk of CRC is positively correlated with
the duration and the anatomic extent of the colitis, the
degree of inflammation, the presence of primer sclerotizing
cholangitis, and a positive family history for CRC [90]. In
case of CDpatients with colonic involvement, the risk of CRC
is similarly elevated to UC patients, while in CD patients
without colonic involvement it is comparable to the general
population [91]. In case of small bowel involvement, the risk
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of small bowel adenocarcinoma is extremely elevated in CD
patients compared to the general population. However, the
overall incidence of disease is low. In the last decades, a
gradual reduction of CRC risk has been observed in IBD
patients, likely due to the effective medical and surgical
treatments [90]. Indeed, population-based studies from the
last decade have found no increased overall risk of CRC
in UC patients compared to the general population, with a
cumulative risk of only 2% in 30 years [92, 93]. Still, in UC
patients with an extensive disease, a slight increase in CRC
risk could be observed [93].
Several data support the hypothesis that the long term
use of 5-ASA decreases the risk of CRC in UC, although
the data are heterogeneous due tomethodological differences
[94]. The ECCO recommends the prolonged use of 5-ASA
to prevent CRC [51]. 5-ASA prevents CRC by interfering
with various mechanisms in CRC cell biology apart from
simply controlling inflammation [95]. Nevertheless, as severe
inflammation is also an independent risk factor for the
development of CRC in UC, theoretically any treatment
that reduces the inflammation can have chemopreventive
effects. A recent study has found that histological severe
inflammation increases the odds ratio of CRC to more than
30 in UC patients, whereas the use of 5-ASA or thiopurines
markedly decreased the risk of CRC [96]. Furthermore, a
case-control study has also demonstrated that treatment with
azathioprine, 6-mercaptopurine, or methotrexate all reduced
CRC risk in UC patients [97]. Anti-TNF-𝛼 therapy has also
been found protective against CRC [98]. Altogether it seems
that any therapy able to induce a complete mucosal healing is
chemoprotective.
7. When to Stop?
It is well known from the clinical practice that the compliance
of patients is rapidly decreasing after they have achieved
remission, and if physicians are reluctant to reduce the
number of tablets, the patients tend to do it themselves.
Therefore it is essential to identify those patient groups where
the maintenance therapy can be discontinued without a high
risk of relapse.
In case of 5-aminosalicylic compounds, many authors are
unanimous in the opinion that 5-ASA should be continued
lifelong in UC patients in remission unless side effects are
present [10, 34]. Nevertheless, it is possible that intermittent
5-ASA therapy, which is associated with lower costs, can be
as effective as continuous therapy [35, 36] and can possibly
be favored by patients, but it should be remembered, that it
is not known if intermittent administration of 5-ASA is still
efficient for chemoprevention.
Regarding methotrexate, further studies on large number
of patients are needed to determine the optimal therapy
duration in IBD, but it seems that relapse rates after therapy
withdrawal are outstandingly high.
In case of azathioprine, for those patients who did not
achieve remission within 6 months, there is probably no
benefit in taking it [12]. However, among those patients
who have reached remission with thiopurines or anti-TNF-
therapies several risk factors predisposing to a relapse after
drug withdrawal have been identified, which are detailed in
Table 5.
These factors can be grouped in different categories
shown in Figure 1, and should be assessed in case of a planned
therapywithdrawal.The absence of surgical resection as a risk
factor does not fit into this picture, as surgical resection is
known to be associated with a more aggressive disease course
[22, 99]. The most important message for the clinician is that
the discontinuation of therapy should be considered only in
those patients, who have a milder disease course and who
are in a complete remission, with no alterations in laboratory
parameters and with a negative colonoscopy. Nevertheless,
mucosal healing should not be a more important endpoint
than the patients’ global well-being and clinical parameters
[31]. As seen in Table 5 and Figure 1, younger and male
patients are at increased risk of relapse, similarly to patients
who have required a more intensive therapy in the past.
The ECCO states that, in case of CD patients in remission
on azathioprine, “cessationmay be considered after four years
of remission. Benefit and risks of continuing azathioprine
should be discussed with individual patients.” [8] In the
study of Treton and colleagues, in a special subgroup of
CD patients in steroid-free remission, who are free from
certain risk factors, such as high CRP level and neutrophil
count, low hemoglobin level, and non-smoking status, no
patients relapsed within 18 months, suggesting that in this
subgroup the treatment can be suspended for a limited time
period, if necessary [18]. This could be an option in case of a
planned pregnancy or breastfeeding, although smoking must
be stopped.
Considering biological treatment, financial factors often
influence the decision on the continuation or withdrawal of
therapy. The introduction of biosimilars in the market will
possibly reduce the present high costs and this may also
be reflected in therapeutic decisions. Until clear guidelines
for the optimal duration of therapy can be formulated, the
opinions of physicians remain quite discrepant. In a question-
naire filled out by Canadian gastroenterologists, 77% would
prefer to continue infliximab treatment indefinitely, if it is
well tolerated and effective, while 12% opted to discontinue it
after 1 year, and 2% would use it for a maximum of 6 months
[100]. One must also keep in mind that similar to steroid-
dependency, dependency fromother treatments, for example,
anti-TNF therapy, can develop in IBD patients [101]. In the
upcoming era of personalized medicine, in the case of CD
patients, where the role of genetic factors in the pathogenesis
is well known, it would be interesting to identify a specific
mutation that predicts a quick relapse after the withdrawal
of therapy. However, a recent study could not identify any
IBD5 and NOD2/CARD15 polymorphisms predictive of the
outcome after withdrawal of infliximab therapy [102].
8. Retreatment after Relapse
After a relapse following a therapy withdrawal, the required
treatment highly depends on the reason of the discon-
tinuation of the drug. If the drug was discontinued due
to side effects or intolerance, then new therapeutic solu-
tions have to be found. Nevertheless, if the drug was well
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High risk of 
relapse after 
withdrawal
Patient-related, noninfluenceable
factors:
(i) younger age
(ii) male gender
More aggressive 
disease course:
(i) perianal disease
(ii) extensive colitis
(iii) lack of sustained 
remission during 
maintenance
More intensive therapy in the 
past, suggesting a more 
aggressive disease course:
(i) higher medication doses 
required
(ii) steroid use in the preceding 
year
(iii) previous anti-TNF therapy
(iv) dose-intensification during 
the 1-year anti-TNF therapy
Clinically active disease:
(i) partial response
severely increased risk
Short treatment/remission
duration:
UCEndoscopically active disease:
Environmental factors:
 (i) smoking in CD
(i) 3–6 months in case of
(ii) <4 years in case of CD
(ii) GRP ≥5mg/L slightly
increased risk;  ≥20mg/L
(iii) leukocyte count >6 × 109/L
(iv) neutrophil count ≥4 × 109/L
(v) hemoglobin ≤145g/L
(vi) fecal calprotectin ≥300𝜇g/g
(i) CDEIS >0
Figure 1: Risk factors predisposing to a relapse after drug withdrawal.
tolerated, the most obvious solution is the reintroduction of
the previously efficacious therapy. Results from studies on
azathioprine or anti-TNF medications show mostly excellent
results with reintroduction of therapy. In the study of Treton
and colleagues, 23 of the 32 relapsed patients were retreated
with azathioprine alone or in combination with steroids,
and among them, 22 have successfully achieved remission
[18]. The only patient who did not respond to azathioprine
alone was suffering dominantly from anoperineal symptoms.
One patient received a combination of azathioprine and
infliximab. The further 8 patients were not retreated with
azathioprine, but four of them were operated for intestinal
stenosis, one was treated with infliximab and three with
methotrexate.
In case of anti-TNF treatment, many data are available
concerning retreatment after withdrawal. In the study of Kim
et al., out of 36 relapsing CD patients, 25 were retreated
with infliximab, and 24 patients (96%) reached complete
clinical remission [28]. One patient among the 25 suffered
an acute severe infusion reaction at the second infliximab
infusion of the new series, which led to the discontinuation
of infliximab. In the same study, 7 out of 10 relapsing UC
patients were retreated with infliximab, which resulted in a
complete clinical remission in 5 patients, partial remission in
one patient, and no effect in one patient, requiring colectomy.
In the Hungarian study on UC patients, infliximab treatment
had to be restarted in 35% of patients, which resulted in a
94% remission, while 6% needed surgery [24]. In the STORI
study, of those 40 patients, who were adequately assessed
30 days after infliximab retreatment, 93% were in remission
and 98% had a clinical response [22]. In this study, available
serum samples were tested for anti-infliximab antibody.
Before retreatment with infliximab, the 39 available serum
samples were found negative, while among the 41 available
serum samples before the second retreatment infusion, 11
were negative and 30 inconclusive. No infusion reaction or
significant delayed reaction has occurred in the retreated
patients up to the third retreatment. In the RASH study, 45%
of CD patients required retreatment with anti-TNF-𝛼 within
one year, which has successfully induced clinical remission in
54.7% of patients, while 9.1% underwent surgery [23]. In case
of reinitiation of therapy, 4% of patients suffered from mild
side effects and 6% had an infusion reaction.
9. Conclusions
Knowledge on the outcome after withdrawal of different
medical therapies in IBD patients who have successfully
achieved remission is constantly growing but is still insuffi-
cient to create universal guidelines. As a final conclusion, the
relapse rates after withdrawal of a well-established therapy
in IBD patients are generally high, but in case of specific
patients, the discontinuation of therapy can be considered.
This decision must be made on an individual basis by the
help of the predictive risk factors detailed above and must
be discussed with the individual patient, after providing all
the necessary information on the risks of the cessation and
the continuation of therapy. More, well-designed prospective
studies are needed to answer all the remaining questions
concerning the optimal duration of therapy in IBD patients
in remission.
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